Biotech · Private company
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Track this companyFree. Adds ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- MiransertibPhase 2 · PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- NemtabrutinibPhase 2 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- ARQ 092 + anastrozolePhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ARQ 092 + carboplatin + paclitaxel (Closed)Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ARQ 092 + paclitaxel (Closed)Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- VevorisertibPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 26, 2017ClinicalTrials.gov NCT03162536 · fetched Nov 12, 2026
- Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)PHASE1_PHASE2 · TERMINATED · started May 16, 2017ClinicalTrials.gov NCT03094832 · fetched Nov 12, 2026
- Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)PHASE1 · TERMINATED · started Jun 26, 2016ClinicalTrials.gov NCT02761694 · fetched Nov 12, 2026
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozolePHASE1 · TERMINATED · started Jun 9, 2015ClinicalTrials.gov NCT02476955 · fetched Nov 12, 2026
- Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior TherapyPHASE3 · COMPLETED · started Dec 27, 2012ClinicalTrials.gov NCT01755767 · fetched Nov 12, 2026
- Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsPHASE1_PHASE2 · COMPLETED · started Dec 10, 2012ClinicalTrials.gov NCT01752920 · fetched Nov 12, 2026
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerPHASE3 · TERMINATED · started Jan 11, 2011ClinicalTrials.gov NCT01244191 · fetched Nov 12, 2026
- Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsPHASE1 · COMPLETED · started Jul 1, 2010ClinicalTrials.gov NCT01149720 · fetched Nov 12, 2026